Benchling is a cloud-based software platform for biology researchers and R&D organizations. It makes life science research faster and more collaborative.
Biotechnology has the potential to solve humanity’s most pressing challenges, such as disease, renewable energy, clean water, and hunger.
Benchling was founded in 2012 by Sajith Wickramasekara, Ashu Singhal, & Cory Li and is headquartered in San Francisco, California.
Benchling focuses on life science collaboration, both private and public, through creating cloud based software tools for digital DNA sequence editing, designing and running experiments, analyzing data, and sharing research.
Benchling offers a modern approach to note-taking. Its collaboration features; integration with Benchling's Bioregistry and Sample Tracking, Molecular Biology Suite, and Workflow Tools; rich search functions; and intuitive user interface encourage usage, so scientists can focus on the science.
Benchling aspires to fix this and increase the rate of scientific output with a web-based platform that allows researchers to design and run experiments, analyze data, and share results.
Benchling is used by hundreds of thousands of scientists using cutting-edge techniques like CRISPR, CAR-T immunotherapy, and genetic engineering, who depend on its suite of cloud applications to design DNA, collaborate on experiments, manage research workflows, and make critical R&D decisions.
Benchling is backed by leading investors including Menlo Ventures, Benchmark, Thrive Capital, Y Combinator, & F-Prime Capital among others. The company raised $34.5M in it's latest funding of a "Series C" round on Jul 24, 2019. This brings Benchling's total funding to $61.9M to-date.